Jon Stoessl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7075033/publications.pdf

Version: 2024-02-01

279 papers	23,671 citations	13865 67 h-index	8630 146 g-index
290 all docs	290 docs citations	290 times ranked	17429 citing authors

#	Article	IF	Citations
1	Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. Neuron, 2004, 44, 601-607.	8.1	2,653
2	A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450
3	Randomized controlled trial of intraputamenal glial cell lineâ€“derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	5.3	890
4	Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. Science, 2001, 293, 1164-1166.	12.6	885
5	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALâ€PET study. Annals of Neurology, 2003, 54, 93-101.	5.3	820
6	DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS. Lancet, The, 1986, 328, 245-247.	13.7	727
7	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
8	Alphaâ€synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Movement Disorders, 2013, 28, 811-813.	3.9	545
9	Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Neurology, The, 2008, 7, 400-408.	10.2	529
10	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology, 2000, 47, 493-503.	5.3	515
11	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	5.7	379
12	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 2004, 127, 2747-2754.	7.6	361
13	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology, 2000, 47, 493-503.	5.3	329
14	Neural transplantation for the treatment of Parkinson's disease. Lancet Neurology, The, 2003, 2, 437-445.	10.2	322
15	Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature, 1985, 317, 246-248.	27.8	309
16	Dopamine release in human ventral striatum and expectation of reward. Behavioural Brain Research, 2002, 136, 359-363.	2.2	303
17	DCTN1 mutations in Perry syndrome. Nature Genetics, 2009, 41, 163-165.	21.4	285
18	Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272

#	Article	IF	Citations
19	DNAJC13 mutations in Parkinson disease. Human Molecular Genetics, 2014, 23, 1794-1801.	2.9	258
20	Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease. Archives of General Psychiatry, 2010, 67, 857.	12.3	244
21	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 2005, 128, 2777-2785.	7.6	242
22	Bilateral human fetal striatal transplantation in Huntingtonâ€™s disease. Neurology, 2002, 58, 687-695.	1.1	234
23	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain, 2009, 132, 2970-2979.	7.6	223
24	Tenâ€year followâ€up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	3.9	221
25	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology, 2001, 49, 298-303.	5.3	205
26	Age-dependent decline of dopamine D1 receptors in human brain: A PET study. , 1998, 30, 56-61.		203
27	Ageâ€specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology, 2011, 69, 803-810.	5.3	197
28	The PARK8 Locus in Autosomal Dominant Parkinsonism: Confirmation of Linkage and Further Delineation of the Disease-Containing Interval. American Journal of Human Genetics, 2004, 74, 11-19.	6.2	195
29	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinsonâ€™s disease. Brain, 2019, 142, 512-525.	7.6	194
30	Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology, 2003, 184, 68-79.	4.1	166
31	The placebo effect in neurological disorders. Lancet Neurology, The, 2002, 1, 85-91.	10.2	164
32	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinsonâ€™s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion, 2018, 34, 2063-2073.	1.9	152
33	Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Movement Disorders, 2003, 18, 157-162.	3.9	151
34	The effects of exercise on cognition in Parkinsonâ€™s disease: a systematic review. Translational Neurodegeneration, 2014, 3, 5.	8.0	139
35	The placebo effect in Parkinson's disease. Trends in Neurosciences, 2002, 25, 302-306.	8.6	138
36	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain, 2011, 134, 3290-3298.	7.6	133

#	Article	IF	Citations
37	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet, The, 2014, 384, 532-544.	13.7	129
38	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Movement Disorders, 2004, 19, 622-629.	3.9	127
39	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. American Journal of Psychiatry, 2002, 159, 768-774.	7.2	123
40	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Annals of Neurology, 2007, 62, 468-474.	5.3	121
41	Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biological Psychiatry, 2004, 56, 67-71.	1.3	119
42	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	2.2	119
43	Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 232-239.	4.3	117
44	SCA-2 presenting as parkinsonism in an Alberta family. Neurology, 2002, 59, 1625-1627.	1.1	113
45	Progression of dopaminergic dysfunction in a LRRK2 kindred. Neurology, 2008, 71, 1790-1795.	1.1	112
46	Presynaptic mechanisms of motor fluctuations in Parkinsonâ€™s disease: a probabilistic model. Brain, 2004, 127, 888-899.	7.6	106
47	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology, 2009, 72, 1211-1216.	1.1	104
48	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Movement Disorders, 2010, 25, 2717-2723.	3.9	103
49	Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders, 2006, 21, 1457-1461.	3.9	102
50	Advances in imaging in Parkinson's disease. Lancet Neurology, The, 2011, 10, 987-1001.	10.2	99
51	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. Movement Disorders, 2019, 34, 1891-1900.	3.9	99
52	Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism and Related Disorders, 2009, 15, 300-306.	2.2	98
53	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurology, The, 2017, 16, 351-359.	10.2	96
54	Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism and Related Disorders, 2009, 15, 281-286.	2.2	89

#	Article	IF	Citations
55	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 301-313.	2.8	89
56	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	3.9	88
57	PET Study of the Effects of Valproate on Dopamine D2Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania. American Journal of Psychiatry, 2002, 159, 1718-1723.	7.2	86
58	Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology, 2012, 78, 649-657.	1.1	85
59	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology, 2001, 49, 298-303.	5.3	85
60	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind videoâ€based analysis. Movement Disorders, 2009, 24, 336-343.	3.9	84
61	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. Neurobiology of Aging, 2017, 57, 248.e7-248.e12.	3.1	83
62	Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 869-876.	4.3	81
63	Nigrostriatal dopamine system and motor lateralization. Behavioural Brain Research, 2000, 112, 63-68.	2.2	76
64	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain, 2006, 129, 1050-1058.	7.6	76
65	Effect of electroconvulsive therapy on brain 5-HT₂ receptors in major depression. British Journal of Psychiatry, 2010, 196, 474-479.	2.8	76
66	Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. Brain Research, 1990, 534, 1-7.	2.2	74
67	Phosphorylated Î±-synuclein in Parkinsonâ€™s disease: correlation depends on disease severity. Acta Neuropathologica Communications, 2015, 3, 7.	5.2	74
68	Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics.. Stroke, 1985, 16, 734-736.	2.0	72
69	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp>arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
70	Invited Article: Functional imaging in Parkinson disease. Neurology, 2008, 70, 1478-1488.	1.1	70
71	Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease. JAMA Neurology, 2021, 78, 1262.	9.0	70
72	VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET. Synapse, 2003, 49, 20-28.	1.2	69

#	Article	IF	Citations
73	Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology, 2006, 66, 1588-1590.	1.1	69
74	Understanding the Placebo Effect: Contributions from Neuroimaging. Molecular Imaging and Biology, 2007, 9, 176-185.	2.6	69
75	Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [¹¹ C]-raclopride and positron-emission tomography. Neurology, 1998, 50, 1028-1032.	1.1	67
76	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain, 2003, 126, 2648-2655.	7.6	63
77	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
78	Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Annals of Neurology, 2008, 63, 388-394.	5.3	62
79	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. Movement Disorders, 2017, 32, 1016-1024.	3.9	62
80	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	3.9	62
81	Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. Journal of Neural Transmission, 2000, 107, 49-57.	2.8	61
82	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology, 2013, 81, 1322-1331.	1.1	60
83	DNAJC12 and dopaâ€responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	5.3	60
84	The NKâ€3 tachykinin receptor agonist senktide elicits 5â€HTâ€mediated behaviour following central or peripheral administration in mice and rats. British Journal of Pharmacology, 1988, 94, 285-287.	5.4	59
85	Neuroimaging in Parkinson's Disease. Neurotherapeutics, 2011, 8, 72-81.	4.4	59
86	Positron emission tomography after fetal transplantation in Huntington's disease. Annals of Neurology, 2005, 58, 331-337.	5.3	57
87	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Lancet Neurology, The, 2018, 17, 309-316.	10.2	57
88	Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology, 1989, 98, 372-379.	3.1	56
89	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics, 2014, 15, 23-30.	1.4	56
90	Glucose utilization: still in the synapse. Nature Neuroscience, 2017, 20, 382-384.	14.8	56

#	Article	IF	Citations
91	Unilateral pallidotomy for reduction of parkinsonian pain. Journal of Neurosurgery, 1999, 91, 198-201.	1.6	55
92	Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Research, 1991, 565, 254-262.	2.2	54
93	Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1151-1159.	4.3	52
94	The Biochemical Bases for Reward. Evaluation and the Health Professions, 2002, 25, 387-398.	1.9	52
95	Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse, 2009, 63, 713-716.	1.2	50
96	Dopamine transporter relation to levodopaâ€derived synaptic dopamine in a rat model of Parkinsonâ€™s: an in vivo imaging study. Journal of Neurochemistry, 2009, 109, 85-92.	3.9	50
97	Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. , 2013, 140, 306-318.		50
98	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders, 2007, 22, 359-365.	3.9	48
99	Localization of striatal and nigral tachykinin receptors in the rat. Brain Research, 1994, 646, 13-18.	2.2	47
100	Etiology of Parkinson's Disease. Canadian Journal of Neurological Sciences, 2003, 30, S10-S18.	0.5	47
101	Lack of Regional Selectivity During the Progression of Parkinson Disease. Archives of Neurology, 2004, 61, 1920-5.	4.5	47
102	Positron emission tomography in premotor Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S421-S424.	2.2	46
103	Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function. Synapse, 2010, 64, 146-151.	1.2	46
104	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki. Parkinsonism and Related Disorders, 2001, 7, 305-309.	2.2	45
105	A Proposed Roadmap for Parkinsonâ€™s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	2.8	45
106	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
107	Pallidotomy for tardive dyskinesia. Lancet, The, 1997, 349, 777-778.	13.7	43
108	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience, 2003, 116, 307-314.	2.3	43

#	Article	IF	Citations
109	Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Molecular Brain Research, 2005, 134, 24-33.	2.3	43
110	COVID-19 and selective vulnerability to Parkinson's disease. Lancet Neurology, The, 2020, 19, 719.	10.2	43
111	Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. Brain Research, 1989, 495, 20-30.	2.2	42
112	Daytime somnolence in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2001, 7, 283-286.	2.2	42
113	DNAJC13 genetic variants in parkinsonism. Movement Disorders, 2015, 30, 273-278.	3.9	42
114	Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders, 1986, 1, 33-44.	3.9	40
115	Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology, 1987, 93, 336-42.	3.1	40
116	Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Research, 1990, 517, 111-116.	2.2	40
117	Autosomal dominant dystonia-plus with cerebral calcifications. Neurology, 2006, 67, 620-625.	1.1	40
118	Dopamine Receptors in Parkinson's Disease: A Metaâ€Analysis of Imaging Studies. Movement Disorders, 2021, 36, 1781-1791.	3.9	40
119	Cerebrospinal fluid amyloid Î² and tau in LRRK2 mutation carriers. Neurology, 2012, 78, 55-61.	1.1	39
120	Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism and Related Disorders, 2012, 18, S55-S59.	2.2	39
121	Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. Prostaglandins, 1977, 14, 819-827.	1.2	38
122	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. Movement Disorders, 2018, 33, 1945-1950.	3.9	37
123	Absence of Mutations in Superoxide Dismutase and Catalase Genes in Patients With Parkinson's Disease. Archives of Neurology, 1995, 52, 1160-1163.	4.5	36
124	Rett Syndrome: Investigation of Nine Patients, including PET Scan. Canadian Journal of Neurological Sciences, 2002, 29, 345-357.	0.5	36
125	Is Axonal Degeneration a Key Early Event in Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2016, 6, 703-707.	2.8	36
126	GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology, The, 2006, 5, 200-202.	10.2	35

#	Article	IF	Citations
127	Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neuroscience Letters, 1987, 80, 321-326.	2.1	34
128	DJ-1 and Î±SYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiology of Aging, 2012, 33, 836.e5-836.e7.	3.1	34
129	Gender differences in Parkinson's disease depression. Parkinsonism and Related Disorders, 2017, 36, 93-97.	2.2	34
130	Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders, 2018, 33, 1213-1227.	3.9	34
131	(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM. Lancet, The, 1985, 326, 1330-1331.	13.7	33
132	Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse, 2003, 47, 152-158.	1.2	33
133	The biochemical bases of the placebo effect. Science and Engineering Ethics, 2004, 10, 143-150.	2.9	33
134	In-vivo Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [¹⁸F]FDOPA PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 59-66.	4.3	33
135	Nemaline Myopathy With Associated Cardiomyopathy. Archives of Neurology, 1985, 42, 1084.	4.5	32
136	Response to Heat Pain Stimulation in Idiopathic Parkinson's Disease. Pain Medicine, 2010, 11, 834-840.	1.9	32
137	Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging. Journal of Parkinson's Disease, 2014, 4, 483-498.	2.8	32
138	Win-Concurrent Sensory Cues Can Promote Riskier Choice. Journal of Neuroscience, 2018, 38, 10362-10370.	3.6	32
139	Environmental Exposures in Elderly Canadians With Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 1995, 22, 232-234.	0.5	30
140	Neuroimaging in the early diagnosis of neurodegenerative disease. Translational Neurodegeneration, 2012, 1, 5.	8.0	30
141	The Nature of Progression in Parkinsonâ€™s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling. PLoS ONE, 2013, 8, e76595.	2.5	30
142	Glucose Use Correlations: A Matter of Inference. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 511-512.	4.3	29
143	A kappa opioid antagonist blocks sensitization in a rodent model of ParkinsonÊ¼s disease. NeuroReport, 1997, 8, 669-672.	1.2	29
144	Clustering of Parkinson Disease. Archives of Neurology, 2004, 61, 1057-60.	4.5	29

#	Article	IF	Citations
145	A family with parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology, 2011, 76, 1623-1630.	1.1	29
146	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Related Disorders, 2001, 7, 81-88.	2.2	27
147	Willing oneself better on placeboâ€"effective in its own right. Lancet, The, 2004, 364, 227-228.	13.7	27
148	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism and Related Disorders, 2009, 15, 539-541.	2.2	27
149	DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 56-61.	2.2	27
150	Movement Disorders in the World of <scp>COVID</scp>â€19. Movement Disorders, 2020, 35, 709-710.	3.9	27
151	Neuroimaging: Current role in detecting preâ€motor Parkinson's disease. Movement Disorders, 2012, 27, 634-643.	3.9	26
152	Dopamine D1A receptor function in a rodent model of tardive dyskinesia. Neuroscience, 2000, 101, 629-635.	2.3	24
153	The placebo response as a reward mechanism. Seminars in Pain Medicine, 2005, 3, 37-42.	0.4	24
154	Etiology of Parkinson's Disease. Canadian Journal of Neurological Sciences, 1999, 26, S5-S12.	0.5	23
155	ParkinsonÊ¼s disease: imaging update. Current Opinion in Neurology, 2002, 15, 477-482.	3.6	23
156	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. NeuroImage: Clinical, 2018, 19, 652-660.	2.7	23
157	Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. Movement Disorders, 2004, 19, 933-936.	3.9	22
158	Biomarkers for trials of neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 71-85.	3.9	22
159	Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. Parkinsonism and Related Disorders, 2016, 22, S47-S51.	2.2	22
160	Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology, 1995, 34, 457-462.	4.1	21
161	Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience, 2002, 112, 851-859.	2.3	21
162	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Progress in Brain Research, 2010, 184, 177-192.	1.4	21

#	Article	IF	Citations
163	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. NeuroImage: Clinical, 2019, 23, 101856.	2.7	21
164	Scans without evidence of dopamine deficiency: The triumph of careful clinical assessment. Movement Disorders, 2010, 25, 529-530.	3.9	20
165	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. EJNMMI Research, 2013, 3, 69.	2.5	20
166	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Movement Disorders, 2014, 29, 1684-1687.	3.9	20
167	Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 756-762.	4.3	19
168	Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity. Synapse, 2000, 37, 171-178.	1.2	19
169	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Translational Neurodegeneration, 2017, 6, 4.	8.0	19
170	The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Movement Disorders, 1993, 8, 445-452.	3.9	18
171	Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease. NeuroImage, 2013, 68, 11-21.	4.2	18
172	Movement Disorders in the World of <scp>COVID</scp>â€19. Movement Disorders Clinical Practice, 2020, 7, 355-356.	1.5	18
173	The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. Psychopharmacology, 1988, 95, 502-6.	3.1	17
174	Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders. Journal of Psychopharmacology, 1989, 3, 99-120.	4.0	17
175	Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. Brain Research, 1991, 558, 289-295.	2.2	17
176	Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. European Journal of Pharmacology, 1994, 259, 301-303.	3.5	17
177	Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. , 1996, 24, 256-261.		17
178	[¹⁸F]â€Dopa positron emission tomography imaging in earlyâ€stage, nonâ€parkin juvenile parkinsonism. Movement Disorders, 2002, 17, 789-794.	3.9	17
179	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. Parkinsonism and Related Disorders, 2009, 15, S13-S16.	2.2	17
180	Central administration of the neurotensin receptor antagonist sr48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience, 2003, 119, 547-555.	2.3	16

#	Article	IF	Citations
181	Gene therapy for Parkinson's disease: a step closer?. Lancet, The, 2014, 383, 1107-1109.	13.7	16
182	DATâ€SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 2014, 29, 1705-1706.	3.9	16
183	Editors' Note: The 200th <scp>A</scp>nniversary of the <scp>S</scp>haking <scp>P</scp>alsy. Movement Disorders, 2017, 32, 1-1.	3.9	16
184	Gene therapy for Parkinson's disease: early data. Lancet, The, 2007, 369, 2056-2058.	13.7	15
185	Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets, 2008, 12, 425-436.	3.4	15
186	In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Movement Disorders, 2014, 29, 1197-1201.	3.9	15
187	Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Current Opinion in Neurology, 1998, 11, 327-333.	3.6	15
188	Imaging striatal dopaminergic function in Phospholipase A2 Group VIâ€“related parkinsonism. Movement Disorders, 2012, 27, 1698-1699.	3.9	14
189	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. Movement Disorders Clinical Practice, 2014, 1, 67-69.	1.5	14
190	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Movement Disorders, 2016, 31, 405-409.	3.9	14
191	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. PLoS ONE, 2018, 13, e0206607.	2.5	14
192	Movement Disorders: New Faces, Same Journal. Movement Disorders, 2020, 35, 1-2.	3.9	14
193	Weeding through the haze: a survey on cannabis use among people living with Parkinsonâ€™s disease in the US. Npj Parkinson's Disease, 2021, 7, 21.	5.3	14
194	Effects of ageing on tachykinin function in the basal ganglia. Brain Research, 1993, 632, 21-28.	2.2	13
195	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Research, 1995, 700, 115-120.	2.2	13
196	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies. Movement Disorders, 2006, 21, 970-975.	3.9	13
197	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. Movement Disorders, 2021, 36, 389-397.	3.9	13
198	Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience, 2000, 98, 61-67.	2.3	12

#	Article	IF	Citations
199	Developments in neuroimaging: positron emission tomography. Parkinsonism and Related Disorders, 2014, 20, S180-S183.	2.2	12
200	The role of biomarkers and imaging in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2016, 16, 187-203.	2.8	12
201	Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. Movement Disorders Clinical Practice, 2017, 4, 607-611.	1.5	12
202	Controlling for Cerebral Atrophy in Positron Emission Tomography Data. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 510-512.	4.3	11
203	Prevention and Management of Late Stage Complications in Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 1992, 19, 113-116.	0.5	11
204	Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Neuroscience, 2002, 112, 261-266.	2.3	11
205	Is there seasonal variation in risk of Parkinson's disease?. Movement Disorders, 2007, 22, 1097-1101.	3.9	11
206	Imaging neural correlates of mild cognitive impairment in Parkinson's disease. Lancet Neurology, The, 2012, 11, 653-655.	10.2	11
207	Central pharmacokinetics of levodopa: Lessons from imaging studies. Movement Disorders, 2015, 30, 73-79.	3.9	11
208	Movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 957-969.	1.8	11
209	Decisions under risk in Parkinsonâ€™s disease: Preserved evaluation of probability and magnitude. Neuropsychologia, 2013, 51, 2679-2689.	1.6	10
210	Imaging in multiple system atrophy. Neurology and Clinical Neuroscience, 2014, 2, 178-187.	0.4	10
211	Dyskinesias and levodopa therapy: why wait?. Journal of Neural Transmission, 2018, 125, 1119-1130.	2.8	10
212	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	3.9	9
213	Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. Cambridge Quarterly of Healthcare Ethics, 2016, 25, 613-622.	0.8	9
214	Optical coherence tomography of patients with Parkinsonâ€™s disease and progressive supranuclear palsy. Clinical Neurology and Neurosurgery, 2020, 189, 105635.	1.4	9
215	Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. European Journal of Pharmacology, 1996, 298, 7-15.	3.5	8
216	Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. Parkinsonism and Related Disorders, 2001, 8, 51-56.	2.2	8

#	Article	IF	Citations
217	Continuous dopaminergic therapy in Parkinson disease: Time to stride back?. Annals of Neurology, 2010, 68, 3-5.	5.3	8
218	Canadian Perspectives on the Clinical Actionability of Neuroimaging in Disorders of Consciousness. Canadian Journal of Neurological Sciences, 2015, 42, 96-105.	0.5	8
219	Dementia in Movement Disorders. Canadian Journal of Neurological Sciences, 1986, 13, 546-558.	0.5	7
220	Differential Diagnosis of Parkinsonism. Canadian Journal of Neurological Sciences, 1999, 26, S1-S4.	0.5	7
221	Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. Nature Clinical Practice Neurology, 2009, 5, 10-11.	2.5	7
222	Salivary gland biopsy for diagnosis of Parkinson's disease?. Lancet Neurology, The, 2016, 15, 654-656.	10.2	7
223	Tau imaging in progressive supranuclear palsy. Movement Disorders, 2017, 32, 91-93.	3.9	7
224	PBB3 binding in a patient with corticobasal syndrome. Movement Disorders, 2018, 33, 1359-1360.	3.9	7
225	Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. Parkinsonism and Related Disorders, 1998, 4, 1-5.	2.2	6
226	Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?. Movement Disorders, 2001, 16, 804-806.	3.9	6
227	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
228	PET Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 177-223.	2.0	6
229	Striatal DAT SPECT: Caveat Emptor!. Movement Disorders, 2019, 34, 1430-1432.	3.9	6
230	Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy. Neuropharmacology, 1993, 32, 555-560.	4.1	5
231	The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat. Neuropharmacology, 1997, 36, 93-99.	4.1	5
232	Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum. Neuroscience, 1997, 76, 1173-1185.	2.3	5
233	Treatment for the progression of Parkinson's disease. Lancet Neurology, The, 2005, 4, 206.	10.2	5
234	Joubert syndrome surviving to adulthood associated with a progressive movement disorder. Movement Disorders, 2007, 22, 262-264.	3.9	5

#	Article	IF	Citations
235	Effects of ethanol in a putative rodent model of tardive dyskinesia. Pharmacology Biochemistry and Behavior, 1996, 54, 541-546.	2.9	4
236	The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCKA receptor antagonist: Evidence for a novel CCK receptor subtype?. Neuropharmacology, 1997, 36, 1679-1688.	4.1	4
237	Agonizing over dopaminergic replacement therapyâ€"lessons from animal models of parkinsonâ€™s disease. Experimental Neurology, 2003, 183, 1-3.	4.1	4
238	Impact of the Spatial Normalization Template and Realignment Procedure on the SPM Analysis of [11C]Raclopride PET Studies. IEEE Transactions on Nuclear Science, 2004, 51, 205-211.	2.0	4
239	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. Canadian Journal of Neurological Sciences, 2005, 32, 277-286.	0.5	4
240	Challenges and unfulfilled promises in Parkinson's disease. Lancet Neurology, The, 2017, 16, 866-867.	10.2	4
241	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. NeuroImage: Clinical, 2020, 25, 102150.	2.7	4
242	Neuroimaging of Sleep and Sleep Disorders. , 2013, , .		4
243	Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. Parkinsonism and Related Disorders, 1996, 2, 167-175.	2.2	3
244	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. Annals of Neurology, 2001, 50, 687-688.	5.3	3
245	Hot spots: Can positron emission tomography offer insights into the pathogenesis of PD?. Annals of Neurology, 2005, 57, 161-162.	5.3	3
246	Movement disorders: new insights into Parkinson's disease. Lancet Neurology, The, 2011, 10, 5-7.	10.2	3
247	Comment: Increased D ₃ bindingâ€"A substrate for levodopa-induced dyskinesias?. Neurology, 2016, 86, 228-228.	1.1	3
248	Neurology in Canada: History of the Canadian Neurological Society. Neurology, 2013, 80, 406-408.	1.1	2
249	Imaging in Parkinsonâ€™s disease: time to look below the neck. Brain, 2015, 138, 512-514.	7.6	2
250	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. Annals of Hepatology, 2019, 18, 651-654.	1.5	2
251	Deception and the ethics of placebo. International Review of Neurobiology, 2020, 153, 147-163.	2.0	2
252	Positron Emission Tomography in Parkinsonâ€™s Disease. , 2005, , 25-35.		2

#	Article	IF	Citations
253	A brain network response to sham surgery. Journal of Clinical Investigation, 2014, 124, 3285-3288.	8.2	2
254	What's New at the Journal in 2022. Movement Disorders, 2022, 37, 1-2.	3.9	2
255	Ethical Issues In The Management Of Parkinsonâ€™S Disease. , 2011, , .		1
256	Liquid Xenon Detectors for Positron Emission Tomography. Journal of Physics: Conference Series, 2011, 312, 062006.	0.4	1
257	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. Parkinsonism and Related Disorders, 2019, 66, 189-194.	2.2	1
258	Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always. Movement Disorders, 2019, 34, 1814-1816.	3.9	1
259	Antisense strategies for the treatment of neurological disease. Expert Opinion on Therapeutic Patents, 2001, 11, 547-562.	5.0	0
260	â€œStiff in the Closetâ€• Who Provides Care for Parkinsonian Patients?. Canadian Journal of Neurological Sciences, 2002, 29, 203-204.	0.5	0
261	On the Use of Clusters to Determine Environmental Influence on Diseaseâ€”Reply. Archives of Neurology, 2005, 62, 331.	4.5	0
262	Neuroimaging of Parkinson's disease. , 2010, , 361-370.		0
263	Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?. Experimental Neurology, 2010, 225, 48-50.	4.1	0
264	Neuroimaging of Parkinsonâ€™s disease and multiple system atrophy in patients with sleep disturbance. , 0, , 305-315.		0
265	Imaging of Dopamine and Serotonin Receptors and Transporters. , 2014, , 241-264.		0
266	The Saskatchewan Movement Disorders Program: Commitment Pays Off. Canadian Journal of Neurological Sciences, 2015, 42, 70-71.	0.5	0
267	Raul de la Fuenteâ€Fernandez, February 22, 1959â€“May 11, 2016. Movement Disorders, 2016, 31, 1144-1145.	3.9	0
268	Reply to letter to the editor: Is there anything more to learn from SWEDD?. Movement Disorders, 2016, 31, 1426-1428.	3.9	0
269	Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context. Canadian Journal of Neurological Sciences, 2018, 45, 633-635.	0.5	0
270	Conclusions. Movement Disorders, 2018, 33, 701-701.	3.9	0

#	Article	IF	Citations
271	Immunotherapy for Parkinson's disease: stay tuned. Lancet Neurology, The, 2020, 19, 561-562.	10.2	0
272	2021: Looking Forward. Movement Disorders, 2021, 36, 11-12.	3.9	0
273	Advances in the Role of Neuroimaging to Monitor Disease Progression in Parkinsonâ€™s Disease. European Neurological Review, 2011, 6, 161.	0.5	0
274	Dopaminergic Imaging in Parkinsonâ€™s Disease: PET. , 2011, , 3-10.		0
275	Insights into LRRK2-Mutation Related PD from PET Imaging Studies. , 2014, , 123-124.		0
276	Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis. , 2014, , 161.		0
277	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism. , 2008, , 75-89.		0
278	Cortical morphology predicts placebo response in multiple sclerosis. Scientific Reports, 2022, 12, 732.	3.3	0
279	Imaging of the Parkinsonian Brain in Relation to Restorative Therapy. , 2006, , 119-130.		0